Principal Financial Group Inc. Has $12.61 Million Position in Catalent, Inc. (NYSE:CTLT)

Principal Financial Group Inc. raised its position in Catalent, Inc. (NYSE:CTLT) by 0.1% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 208,206 shares of the company’s stock after buying an additional 229 shares during the period. Principal Financial Group Inc. owned about 0.11% of Catalent worth $12,611,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in CTLT. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Catalent by 1.1% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after purchasing an additional 220 shares during the period. Crossmark Global Holdings Inc. grew its position in shares of Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after buying an additional 229 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in shares of Catalent by 3.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock worth $432,000 after buying an additional 278 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Catalent by 26.9% in the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after buying an additional 278 shares during the period. Finally, Longfellow Investment Management Co. LLC boosted its stake in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares during the last quarter.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

CTLT has been the topic of a number of analyst reports. StockNews.com assumed coverage on Catalent in a research note on Friday. They issued a “hold” rating on the stock. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Eight analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

Shares of Catalent stock opened at $63.48 on Friday. The company has a market capitalization of $11.52 billion, a P/E ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The business has a 50-day moving average of $60.89 and a two-hundred day moving average of $59.56. Catalent, Inc. has a 1 year low of $41.15 and a 1 year high of $63.50.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.10) earnings per share. As a group, equities analysts predict that Catalent, Inc. will post 0.78 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.